China - Chengdu Lead Drug Development Co., Ltd. (stock code: 688222.SH, hereinafter referred to as 'Chengdu Lead'), a company listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, announced its alliance with Structural Genomics (Structural Genomics Consortium, hereinafter referred to as 'SGC') to establish a partnership.
HitGen will use OpenDEL, a product of its DNA-encoded library (DEL) technology platform, to screen new targets of interest to SGC. The project's screening dataset will be released on a public platform in a format suitable for ML (machine learning) so that drug discovery and ML experts around the world can access, conduct data modeling, and apply it to predict new active molecules. As part of the 'Target 2035' initiative of the global open science movement, the predicted new active molecules will be experimentally tested at the SGC.
HitGen is a global leader in the development of DEL technology and its application in the research and development of new small molecule drugs. Its DEL technology platform can design, synthesize and screen physical molecular libraries containing more than 1.2 trillion DNA-encoded compounds. The company's DEL products and efficient screening capabilities have provided new drug discovery services and projects to many institutions and organizations around the world.
OpenDEL is a self-service DEL screening service product with a total number of compounds reaching 3 billion. Users can conduct DEL screening without revealing target information. Under the guidance of the product manual and operating instructions, users can independently complete affinity screening experiments for protein targets. At the same time, Chengdu Pioneer can also provide upstream and downstream technical services.
Dr. Li Jin, Chairman and CEO of HitGen, said: 'We look forward to collaborating with SGC's research team to develop novel compound starting points for under-studied protein targets and open relevant data sets on public platforms for AI/ ML (artificial intelligence/machine learning) research. Chengdu HitGen has the world's leading DEL technology platform, which is an efficient 'engine' for discovering new drug 'seeds'. As one of the company's four core technology platforms, the DEL technology platform has already provided services for many customers Innovative drug discovery projects with partners provide novel starting compounds. We are also looking forward to screening valuable starting compounds for the targets that SGC focuses on.'
Aled Edwards, CEO of SGC, said: 'I believe that this cooperation between the two parties is expected to have a transformative impact. We look forward to providing high-quality, carefully organized data to the field of ML (machine learning), using ML to find all human The starting point for drug research on protein targets.'
About Chengdu Pioneer
Chengdu HitGen Drug Development Co., Ltd. (Shanghai Stock Exchange stock code: 688222.SH, stock name: Chengdu HitGen) is committed to building a world-class innovative biopharmaceutical company. It is headquartered in Chengdu, China, with offices in Cambridge, UK, and Houston, USA. subsidiaries. The company focuses on the discovery and optimization of new small molecule and nucleic acid drugs, strives to build an internationally leading DNA- encoded compound library technology platform (including the design, synthesis, screening and expanded application of DEL libraries), and expands the platform based on molecular fragments and three-dimensional structural information. Core technology platform for drug design technology (FBDD/SBDD), oligonucleotide new drug development related technology and targeted protein degradation related technology. Through diversified business models such as new drug research and development services, transfer of research projects at different stages, and long-term drug launch, Chengdu HitGen has established cooperation with hundreds of pharmaceutical companies, biotechnology companies, chemical companies, foundations and scientific research institutions around the world. Currently, the company has multiple internal new drug projects in different clinical and preclinical stages.
About the Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a global public-private partnership that aims to accelerate drug discovery by promoting collaboration between scientists in academia and industry and making all research results available to the scientific community. Currently, SGC's research bases are located at Goethe University Frankfurt, Karolinska Institutet, McGill University, University College London, University of North Carolina at Chapel Hill, and University of Toronto.
Contact:
Tel: +86-28-8519-7385
HITGEN INC. 
